Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
United Food and Commercial Workers Unions and Employers Midwest Health Benefits Fund et al v. Novartis Pharmaceuticals Corporation et al
Case Number:
1:15-cv-12732
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Arnold & Porter
- Dugan Law Firm
- Hagens Berman
- Herzfeld Suetholz
- Lockridge Grindal
- McCarter & English
- Morrison Foerster
- Proskauer Rose
- Radice Law Firm
- Shapiro Haber
- Spector Roseman
- Stranch Jennings
- Wexler Boley
Companies
- American Federation of State County & Municipal Employees
- Novartis AG
- United Food & Commercial Workers International Union
Sectors & Industries:
-
June 30, 2017
Novartis Escapes End Payors' Gleevec Antitrust Suit
A Massachusetts federal judge on Friday granted Novartis Pharmaceuticals Corp.'s bid to toss a proposed class action alleging the company participated in an anti-competitive scheme to extend its monopoly on leukemia drug Gleevec.
-
May 10, 2017
Novartis Says Gleevec Antitrust Suit Should Remain Paused
End payors accusing Novartis Pharmaceuticals of violating antitrust laws by filing an invalid patent for leukemia drug Gleevec and starting sham litigation over it shouldn't get to try to lift a stay on fact-finding, the company told a Massachusetts federal court Wednesday.
-
August 01, 2016
Novartis Leukemia Drug Buyers Blast 'Sham' Patent Suit
Third-party purchasers of a Novartis leukemia drug told a Massachusetts federal judge Monday that the company lied to patent examiners about how easy it was to come up with the $2 billion-a-year formulation, then violated antitrust law by engaging in "sham" litigation to protect its patent for another eight months.
-
June 10, 2016
Buyers Say Gleevec Antitrust Suit Should Proceed
A proposed class of purchasers asked a Massachusetts federal court Thursday to keep alive its antitrust suit over Novartis Pharmaceuticals Corp.'s leukemia drug Gleevec, saying the company's patent application and infringement litigation were shams that violated antitrust laws.
-
August 21, 2015
Novartis Can't Nix Gleevec Antitrust Suit, Buyers Say
A proposed putative class of purchasers pushed back Thursday against arguments by Novartis Pharmaceuticals Corp. that they lack standing to challenge the validity of leukemia drug Gleevec's patent, claiming their focus is actually on the company's alleged antitrust activity.
-
July 30, 2015
Novartis Looks To Kill Gleevec Antitrust Suit
Novartis Pharmaceuticals Corp. told a Massachusetts federal judge to dismiss a proposed class action that claims the company illegally withheld generic versions of a leukemia drug from consumers, saying the plaintiffs lack standing to sue and have failed to state a claim.
-
June 23, 2015
Novartis Hit With Gleevec Sham Litigation Class Action
Novartis Pharmaceuticals Corp. conspired to improperly withhold generic versions of Gleevec — a blockbuster leukemia medication — from the consumer market, two employee welfare funds alleged in a proposed class action filed on Monday in Massachusetts federal court.